The ever-expanding research on human cancer has resulted in numerous technical and conceptual advances during the last few years. Serological, structural, and biological char acterization of human melanoma constitutes one area of research that has received consid erable attention from researchers and clinicians and has generated new and exciting infor mation. In this volume, we have attempted to assemble work on topics that produced some of the most recent advances. We asked each author to describe and interpret his most cur rent research and, whenever possible, to compare and contrast it with work of other inves tigators in the field. We have been careful not to impose our viewpoints except in contri butions from our own laboratories, since we want to provide the reader with as many divergent and sometimes opposing viewpoints as feasible. Therefore, we have not been overly concerned with overlaps in some individual topics. We hope that this volume will provide the reader with a well-balanced overview of current problems and ideas in a par ticular area of cancer research. We wish to express our thanks to all contributors for their timely and very interesting manuscripts, and we sincerely hope that the reader will enjoy this volume and benefit as much from it as we did. R. A. Reisfeld S. Ferrone La Jolla ix Contents CHAPTER 1 Immunogenetics of Melanoma RONALD T. ACTON, CHARLES M. BALCH, BRUCE BUDOWLE, RODNEY C. P. Go, JEFFREY M. ROSEMAN, SENG-jAW SOONG, AND BRUCE O. BARGER 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.